JP2011521896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011521896A5 JP2011521896A5 JP2011505028A JP2011505028A JP2011521896A5 JP 2011521896 A5 JP2011521896 A5 JP 2011521896A5 JP 2011505028 A JP2011505028 A JP 2011505028A JP 2011505028 A JP2011505028 A JP 2011505028A JP 2011521896 A5 JP2011521896 A5 JP 2011521896A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- antagonist
- lfa
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000005557 antagonist Substances 0.000 claims description 51
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 48
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 48
- 125000001072 heteroaryl group Chemical group 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000001931 aliphatic group Chemical group 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 24
- 150000002431 hydrogen Chemical class 0.000 claims description 24
- 125000002723 alicyclic group Chemical group 0.000 claims description 22
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 22
- -1 heteroaliphatic Chemical group 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 7
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 125000002070 alkenylidene group Chemical group 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- BWOVZCWSJFYBRM-UHFFFAOYSA-N carbononitridic isocyanate Chemical group O=C=NC#N BWOVZCWSJFYBRM-UHFFFAOYSA-N 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000003889 eye drop Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 229940051250 hexylene glycol Drugs 0.000 claims description 4
- 230000001050 lubricating effect Effects 0.000 claims description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 4
- 229960002216 methylparaben Drugs 0.000 claims description 4
- 239000003961 penetration enhancing agent Substances 0.000 claims description 4
- 229920005862 polyol Polymers 0.000 claims description 4
- 150000003077 polyols Chemical class 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 3
- JTNFLOSMZURXJM-UHFFFAOYSA-N NS(S)(=O)=O Chemical compound NS(S)(=O)=O JTNFLOSMZURXJM-UHFFFAOYSA-N 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- VCJIGSOOIYBSFA-UHFFFAOYSA-N azido formate Chemical compound [N-]=[N+]=NOC=O VCJIGSOOIYBSFA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000227 bioadhesive Substances 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 230000002860 competitive effect Effects 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- 239000011859 microparticle Substances 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000011505 plaster Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229960003415 propylparaben Drugs 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 3
- 239000002525 vasculotropin inhibitor Substances 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- NMLMACJWHPHKGR-NCOIDOBVSA-N P(1),P(4)-bis(uridin-5'-yl) tetraphosphate Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C(NC(=O)C=C2)=O)O)O)C=CC(=O)NC1=O NMLMACJWHPHKGR-NCOIDOBVSA-N 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 claims description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 2
- 229940046731 calcineurin inhibitors Drugs 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 239000008139 complexing agent Substances 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229950003529 diquafosol Drugs 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 229940012356 eye drops Drugs 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000003979 granulating agent Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 229910003002 lithium salt Inorganic materials 0.000 claims description 2
- 159000000002 lithium salts Chemical class 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 229960002969 oleic acid Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000019271 petrolatum Nutrition 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 229950004535 rebamipide Drugs 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 159000000000 sodium salts Chemical group 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 150000003462 sulfoxides Chemical group 0.000 claims description 2
- 150000003505 terpenes Chemical class 0.000 claims description 2
- 235000007586 terpenes Nutrition 0.000 claims description 2
- 229960004418 trolamine Drugs 0.000 claims description 2
- 239000003871 white petrolatum Substances 0.000 claims description 2
- 150000003751 zinc Chemical class 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 150000007513 acids Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- 238000000034 method Methods 0.000 description 20
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 6
- 206010023332 keratitis Diseases 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 0 *C(c1c(CC2(*)*)c(*)c(C(NC(*)(*)*)=O)c(*)c1)N2I* Chemical compound *C(c1c(CC2(*)*)c(*)c(C(NC(*)(*)*)=O)c(*)c1)N2I* 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000031709 Skin Manifestations Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- RYPKRALMXUUNKS-UHFFFAOYSA-N hex-2-ene Chemical group CCCC=CC RYPKRALMXUUNKS-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010030983 oral lichen planus Diseases 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
- 210000001745 uvea Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4524008P | 2008-04-15 | 2008-04-15 | |
| US61/045,240 | 2008-04-15 | ||
| PCT/US2009/002389 WO2009128934A1 (en) | 2008-04-15 | 2009-04-15 | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014080832A Division JP2014132032A (ja) | 2008-04-15 | 2014-04-10 | 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011521896A JP2011521896A (ja) | 2011-07-28 |
| JP2011521896A5 true JP2011521896A5 (enExample) | 2012-06-07 |
Family
ID=41164200
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505028A Withdrawn JP2011521896A (ja) | 2008-04-15 | 2009-04-15 | 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト |
| JP2014080832A Pending JP2014132032A (ja) | 2008-04-15 | 2014-04-10 | 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014080832A Pending JP2014132032A (ja) | 2008-04-15 | 2014-04-10 | 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20090258070A1 (enExample) |
| EP (2) | EP3632444A3 (enExample) |
| JP (2) | JP2011521896A (enExample) |
| CN (1) | CN102056485A (enExample) |
| ES (1) | ES2763703T3 (enExample) |
| WO (1) | WO2009128934A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2544678C (en) | 2003-11-05 | 2013-12-31 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
| AU2006247136C1 (en) | 2005-05-17 | 2020-01-16 | Bausch + Lomb Ireland Limited | Compositions and methods for treatment of eye disorders |
| DK1915620T3 (da) | 2005-08-02 | 2010-10-04 | Xbiotech Inc | Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer |
| MX2010004281A (es) | 2007-10-19 | 2010-09-10 | Sarcode Corp | Composiciones y metodos para el tratamiento de la retinopatia diabetica. |
| US20090257957A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders |
| CN102065893A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | Lfa-1拮抗剂向胃肠系统的递送 |
| PL3085773T3 (pl) | 2008-05-30 | 2021-01-11 | Xbiotech, Inc | Zastosowanie przeciwciał il-1 alfa |
| JP5976319B2 (ja) | 2008-09-12 | 2016-08-23 | エックスバイオテク, インコーポレイテッドXbiotech, Inc. | 病原性単球の標的化 |
| AU2009296458A1 (en) * | 2008-09-26 | 2010-04-01 | Nanobio Corporation | Nanoemulsion therapeutic compositions and methods of using the same |
| WO2010093992A1 (en) * | 2009-02-13 | 2010-08-19 | Topica Pharmaceuticals, Inc | Anti-fungal formulation |
| US20120022102A1 (en) * | 2010-01-20 | 2012-01-26 | Cadila Healthcare Limited | Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof |
| US20110311547A1 (en) | 2010-06-18 | 2011-12-22 | Xbiotech, Inc. | Arthritis Treatment |
| KR20210128021A (ko) | 2010-08-23 | 2021-10-25 | 얀센 바이오테크 인코포레이티드 | 종양성 질병들에 대한 치료 |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| ES2695102T3 (es) | 2011-09-23 | 2019-01-02 | Xbiotech Inc | Tratamiento para la caquexia |
| WO2013108644A1 (ja) * | 2012-01-20 | 2013-07-25 | 京都府公立大学法人 | レバミピドのアレルギー性結膜炎治療剤 |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| CN104955453B (zh) | 2012-12-19 | 2018-09-18 | 原生质生物科学股份有限公司 | Lfa-1抑制剂制剂 |
| US9688943B2 (en) | 2015-05-29 | 2017-06-27 | beauty Avenues LLC | Candle containing non-ionic emulsifer |
| CN110087636A (zh) * | 2016-12-16 | 2019-08-02 | 萨可德生物科学公司 | 利非斯特制剂的眼部分布和药代动力学 |
| MX2019009798A (es) | 2017-02-16 | 2020-01-30 | Xbiotech Inc | Tratamiento de la hidradenitis supurativa. |
| CN106920239B (zh) * | 2017-03-08 | 2019-10-18 | 福建师范大学 | 一种基于改进sift算法的图像关键点检测方法 |
| TW201920956A (zh) * | 2017-09-29 | 2019-06-01 | 日商參天製藥股份有限公司 | 淚液中之muc5ac量之測定方法 |
| CN111787918A (zh) * | 2017-11-29 | 2020-10-16 | 洛克菲勒大学 | 用于皮肤病学病况增强治疗的局部和全身性治疗的组合 |
| EP3955926A4 (en) * | 2019-04-18 | 2022-11-30 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| CA3147431A1 (en) | 2019-07-16 | 2021-01-21 | Donaghys Limited | Transdermal solvent system and methods of use |
| EP3797771B1 (en) * | 2019-09-03 | 2022-02-23 | Square Power Ltd | Rebamipide for use in prophylaxis and treatment of celiac disease |
| CN112494488B (zh) * | 2020-06-17 | 2022-01-18 | 中国药科大学 | 瑞巴派特的防脱发和生发用途 |
| US12393057B2 (en) * | 2020-12-15 | 2025-08-19 | Coopervision International Limited | Oleic acid-releasing contact lens |
| CA3204617A1 (en) * | 2020-12-29 | 2022-07-07 | Next Science IP Holdings Pty Ltd | Cancer treatment composition and method |
| CA3216947A1 (en) * | 2021-06-14 | 2022-12-22 | Protransit Nanotherapy Llc | Cyclosporine compositions and methods of use thereof |
| CN115707698A (zh) * | 2021-08-18 | 2023-02-21 | 辽宁何氏医学院 | 5,7-二氯-1,2,3,4-四氢异喹啉-6-甲酰胺类化合物及其制备方法和应用 |
| EP4589369A1 (en) * | 2022-09-15 | 2025-07-23 | NOF Corporation | Solution for contact lenses |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
| WO2025223511A1 (zh) * | 2024-04-25 | 2025-10-30 | 上海翊石医药科技有限公司 | 一类苯甲酰基甘氨酸衍生物及其制备方法和应用 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) * | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4316893A (en) | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| US4524008A (en) | 1983-12-16 | 1985-06-18 | E. I. Du Pont De Nemours And Company | Controlled initiation chromium dioxide synthesis |
| US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| DE3802996A1 (de) | 1988-02-02 | 1989-08-10 | Cassella Ag | Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen |
| US5424399A (en) * | 1988-06-28 | 1995-06-13 | The Children's Medical Center Corporation | Human CR3α/β heterodimers |
| US5149780A (en) * | 1988-10-03 | 1992-09-22 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
| AU8631991A (en) * | 1990-08-27 | 1992-03-17 | Cetus Corporation | Cd18 peptide medicaments for the treatment of disease |
| US5288854A (en) * | 1990-11-28 | 1994-02-22 | Center For Blood Research, Inc. | Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1 |
| CA2120506C (en) * | 1991-10-04 | 2000-12-12 | Scott M. Whitcup | Treatment of ocular inflammation by blockage of cell adhesion molecules |
| US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US6162432A (en) * | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| EP0628057B1 (en) * | 1992-02-28 | 1999-10-20 | Board Of Regents The University Of Texas System | Use of a therapeutical COMPOSITION FOR THE TREATMENT OF THERMAL INJURY |
| US5298492A (en) * | 1992-08-04 | 1994-03-29 | Schering Corporation | Diamino acid derivatives as antihypertensives |
| ATE161192T1 (de) | 1992-08-21 | 1998-01-15 | Genentech Inc | Verfahren zur behandlung einer durch lfa-1 vermittelten störung |
| US5397791A (en) * | 1993-08-09 | 1995-03-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| DK0656348T3 (da) * | 1993-12-03 | 2000-09-11 | Hoffmann La Roche | Eddikesyrederivater som medikamenter |
| US5470953A (en) * | 1993-12-23 | 1995-11-28 | Icos Corporation | Human β2 integrin α subunit |
| US6228383B1 (en) | 1994-03-03 | 2001-05-08 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
| EP0762886A4 (en) | 1994-04-19 | 1999-03-31 | Univ Kansas | ICAM-1 / LFA-1 SHORT CHAIN PEPTIDES AND METHODS FOR USE THEREOF |
| US5585359A (en) * | 1994-09-29 | 1996-12-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP0710657B1 (de) * | 1994-11-02 | 1998-08-26 | MERCK PATENT GmbH | Adhäsionsrezeptor-Antagonisten |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| ATE342295T1 (de) | 1995-07-28 | 2006-11-15 | Genzyme Corp | Biologische abbaubare multiblokhydrogene und ihre verwendung wie trägerstoffe fur kontrollierte freisetzung pharmakologisch activen werstoffe und gewebekontaktmaterialen |
| CA2272565A1 (en) * | 1996-11-27 | 1998-06-04 | Du Pont Pharmaceuticals Company | Integrin receptor antagonists |
| AR013445A1 (es) | 1997-08-28 | 2000-12-27 | Novartis Ag | Antagonistas de lfa-1 |
| US6541606B2 (en) * | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
| JP2002509881A (ja) | 1998-03-27 | 2002-04-02 | ジェネンテク・インコーポレイテッド | Ｃｄ１１／ｃｄ１８接着レセプター媒介疾患の治療用アンタゴニスト |
| US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| US6670321B1 (en) * | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
| ATE330631T1 (de) * | 1999-01-05 | 2006-07-15 | Univ Southern Australia | Antikörperfragmente zur lokalen behandlung von augenerkrankungen |
| EP1028114A1 (en) * | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| KR100567292B1 (ko) * | 1999-12-14 | 2006-04-04 | 제넨테크, 인크. | Ｌｆａ-1 또는 ｔｎｆ-알파 매개 질환의 치료용ｔｎｆ-알파 길항제 및 ｌｆａ-1 길항제 |
| US6630447B2 (en) | 2000-01-14 | 2003-10-07 | University Of New Mexico | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| US6515124B2 (en) | 2000-02-09 | 2003-02-04 | Hoffman-La Roche Inc. | Dehydroamino acids |
| WO2001085677A1 (fr) * | 2000-05-05 | 2001-11-15 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derives d'aminoacides et leur application a titre de medicaments |
| CN1705649A (zh) * | 2000-06-29 | 2005-12-07 | 艾伯特公司 | 芳基苯基杂环基硫醚衍生物及其作为抑制细胞粘附的抗炎和免疫抑制剂的用途 |
| AR030817A1 (es) * | 2000-10-02 | 2003-09-03 | Novartis Ag | Derivados de diazacicloalcanodiona |
| US6653478B2 (en) * | 2000-10-27 | 2003-11-25 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators |
| GB0028367D0 (en) * | 2000-11-21 | 2001-01-03 | Celltech Chiroscience Ltd | Chemical compounds |
| CN1592746A (zh) | 2000-11-28 | 2005-03-09 | 杰南技术公司 | Lfa－1拮抗剂化合物 |
| ATE348829T1 (de) * | 2001-02-06 | 2007-01-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen |
| WO2002098370A2 (en) * | 2001-03-02 | 2002-12-12 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
| US6391290B1 (en) | 2001-03-21 | 2002-05-21 | Schering-Plough Healthcare Products, Inc. | Skin care compositions |
| US6872382B1 (en) * | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| EP1392306B1 (en) * | 2001-06-06 | 2008-01-16 | Aventis Pharma Limited | Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases |
| WO2003009740A2 (en) * | 2001-07-24 | 2003-02-06 | Biogen Idec Ma Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
| RU26988U1 (ru) | 2002-05-06 | 2003-01-10 | Закрытое акционерное общество "ДУКС-ЛИЗИНГ" | Кондуктор для сверления отверстий |
| AU2003248627A1 (en) * | 2002-06-06 | 2003-12-22 | Dana-Farber Cancer Institute | Compounds or agents that inhibit and induce the formation of focal microvessel dilatations |
| US7785578B2 (en) * | 2002-10-11 | 2010-08-31 | Aciont, Inc. | Non-invasive ocular drug delivery |
| CA2544678C (en) * | 2003-11-05 | 2013-12-31 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
| CN1902195B (zh) * | 2003-11-05 | 2016-03-23 | 萨可德生物科学公司 | 细胞粘着调节剂 |
| WO2005065668A2 (en) * | 2003-12-29 | 2005-07-21 | Qlt Usa, Inc. | Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders |
| JP2008507592A (ja) * | 2004-06-09 | 2008-03-13 | ジェネンテック・インコーポレーテッド | 環状肉芽腫又はサルコイドの治療法 |
| EP1773322A1 (en) * | 2004-07-22 | 2007-04-18 | Wyeth | Method for treating nervous system disorders and conditions |
| AU2006247136C1 (en) * | 2005-05-17 | 2020-01-16 | Bausch + Lomb Ireland Limited | Compositions and methods for treatment of eye disorders |
| MX2010004281A (es) * | 2007-10-19 | 2010-09-10 | Sarcode Corp | Composiciones y metodos para el tratamiento de la retinopatia diabetica. |
| US8080562B2 (en) * | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| US20090257957A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders |
| CN102065893A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | Lfa-1拮抗剂向胃肠系统的递送 |
| WO2011050175A1 (en) * | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| JP6607780B2 (ja) * | 2012-07-25 | 2019-11-20 | サルコード・バイオサイエンス・インコーポレイテッド | Ｌｆａ−１阻害剤およびその多形 |
-
2009
- 2009-04-15 WO PCT/US2009/002389 patent/WO2009128934A1/en not_active Ceased
- 2009-04-15 EP EP19191575.0A patent/EP3632444A3/en not_active Withdrawn
- 2009-04-15 JP JP2011505028A patent/JP2011521896A/ja not_active Withdrawn
- 2009-04-15 CN CN2009801216301A patent/CN102056485A/zh active Pending
- 2009-04-15 EP EP09733509.5A patent/EP2265125B1/en active Active
- 2009-04-15 US US12/386,359 patent/US20090258070A1/en not_active Abandoned
- 2009-04-15 ES ES09733509T patent/ES2763703T3/es active Active
-
2013
- 2013-08-07 US US13/961,117 patent/US20140051722A1/en not_active Abandoned
-
2014
- 2014-04-10 JP JP2014080832A patent/JP2014132032A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011521896A5 (enExample) | ||
| JP2011518155A5 (enExample) | ||
| JP2011516607A5 (enExample) | ||
| SK147493A3 (en) | Antialergic substances for the use in ophthalmologic and otorhynologic | |
| US7084157B2 (en) | Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation | |
| KR20090114398A (ko) | (ｅ)-2,6-다이알콕시스티릴 4-치환된 벤질설폰의 비경구 투여용 제형 | |
| US20060014786A1 (en) | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation | |
| US12290497B2 (en) | Agent containing 4-phenylbutyrate, for preventing or treating presbyopia | |
| JP3131693B2 (ja) | 眼疾患を処置するための５―メチル―イソオキサゾール―４―カルボン酸アニリド類または２―ヒドロキシエチリデン―シアノ酢酸アニリド類含有医薬組成物 | |
| US11241426B2 (en) | Aqueous composition for ophthalmic or nasal administration | |
| US11331311B2 (en) | Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound | |
| EP1889620A1 (en) | Eye drop containing roflumilast | |
| JP2003128549A (ja) | 粘膜適用組成物 | |
| JPH06316519A (ja) | 薬剤で誘導される瞳孔拡大を抑制し又は拡大された瞳孔を 縮小するための、一定のスルファモイル置換フェネチルア ミン誘導体の使用、及びそれに用いる局部的投与組成物 | |
| PL208284B1 (pl) | Pochodne benzo[g]chinoliny, kompozycje je zawierające oraz zastosowanie takich pochodnych | |
| JP5214966B2 (ja) | ２−アミノ−１，３−プロパンジオール化合物およびその類似体の製剤 | |
| EP4099986B1 (en) | Xanthan-based ophthalmic topical formulations with a reduced dosage regimen | |
| JP2016210780A (ja) | アゾール系抗真菌薬の眼瞼皮膚への投与 | |
| JP7682103B2 (ja) | シロリムスまたはその塩を含有する水性懸濁組成物 | |
| JP2020514347A (ja) | チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤 | |
| CN101432000B (zh) | 用于变应性眼病或变应性鼻病的包含三环性三唑并苯并氮杂*衍生物的预防剂或治疗剂 | |
| JP4779382B2 (ja) | 点眼剤用組成物 | |
| KR20160072829A (ko) | 테노포비어, 항균제 및 선택적으로 시클로피록스를 포함하는 국소 약학 조성물 | |
| JP2003201250A (ja) | 掻痒治療剤 | |
| US20080015255A1 (en) | Pharmaceutical Compositions Based on Fluorinated Sulphamides and Sulphinimides |